Skip to main content
SpringerLink
Log in

Negative symptoms in schizophrenia: considerations for clinical trials

Working group on negative symptoms in schizophrenia

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abrams R, Taylor MA (1978) A rating scale for emotional blunting. Am J Psychiatry 135:226–229

    Google Scholar 

  • Alphs LD, Summerfelt A, Lann H, Muller RJ (1989) The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 25:159–163

    Google Scholar 

  • AMDP (1981) Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. Springer, Berlin

    Google Scholar 

  • American Psychiatric Association (1993) DSM-IV Draft Criteria. American Psychiatric Association, Washington, pp I:1-I:3

    Google Scholar 

  • Andreasen N (1981) Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City

    Google Scholar 

  • Andreasen N (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784–788

    Google Scholar 

  • Angst J, Bech P, Bobon D, Engel R, Hippius H, Janzen GJ, Lecrubier Y, Lingjaerde O, Möller H-J, Montgomery S, Paes de Sousa M, Rossi A, Saletu B, Sedvall G, Stefanis C, Stoll K-D, Woggon B (1991) Report on the 3rd Consensus Conference on the methodology of clinical trials with anti-psychotic drugs. Pharmacopsychiatry 24:149–152

    Google Scholar 

  • Awad AG (1992) Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 43:262–265

    Google Scholar 

  • Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D (1992) The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. J Nerv Ment Dis 180:723–728

    Google Scholar 

  • Bunney WE, Hamburg DA (1963) Methods for reliable longitudinal observationof behavior. Arch Gen Psychiatry 9:280–294

    Google Scholar 

  • Carpenter WT, Buchanan RW, Kirkpatrick B (1990) The concept of the negative symptoms of schizophrenia. In: Greden JF, Tandon R (eds) Negative schizophrenic symptoms: pathophysiology and clinical implications. American Psychiatric Press, Washington DC, pp 5–20

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? BMJ 180:66

    Google Scholar 

  • Czobor P, Bitter I, Volavka J (1991) Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Res 36:129–139

    Google Scholar 

  • Endicott J, Spitzer RL (1978) A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837–844

    Google Scholar 

  • Hasemann K (1983) Verhaltensbeobachtung und Ratingverfahren. In: Groffmann K-J, Michel L (eds) Verhaltensdiagnostik, Hogrefe, Göttingen

    Google Scholar 

  • Heinrichs DW, Hanlon TE, Carpenter WT (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–396

    Google Scholar 

  • Honigfeld G, Klett CJ (1965) The Nurses Observation Scale for Inpatient Evaluation. J Clin Psychol 21:65–71

    Google Scholar 

  • Husted JA, Beiser M, Iacono WG (1992) Negative symptoms and the early course of schizophrenia. Psychiatry Res 43:215–222

    Google Scholar 

  • Iager AC, Kirch DG, Wyatt RJ (1985) A negative symptom rating scale. Psychiatry Res 16:27–36

    Google Scholar 

  • Kane JM, Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment? Br J Psychiatry 155 [suppl. 7]:115–118

    Google Scholar 

  • Katz MM, Lyerly SB (1963) Methods for measuring adjustment and social behavior in the community: rationale, description, discriminative validity and scale development. Psychol Rep 11:503–535

    Google Scholar 

  • Kay SR (1990) Significance of the positive-negative distinction in schizophrenia. Schizophr Bull 16 [4]:636–652

    Google Scholar 

  • Kay SR, Murrill LM (1990) Predicting outcome of schizophrenia. Significance of symptom profiles and outcome dimensions. Compr Psychiatry 31:91–102

    Google Scholar 

  • Kay SR, Sevy S (1990) Pyramidical model in schizophrenia. Schizophr Bull 16:537–545

    Google Scholar 

  • Kay SR, Fiszbein A, Lindenmayer JP, Opler LA (1986) Positive and negative symptoms in schizophrenia as a function of chronicity. Acta Psychiatr Scand 74:507–518

    Google Scholar 

  • Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 [2]:261–276

    Google Scholar 

  • Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–124

    Google Scholar 

  • Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 55:299–308

    Google Scholar 

  • Liddle PF (1987) The symptoms of chronic schizophrenia: a reexamination of the positive-negative dichotomy. Br J Psychiatry 151:145–151

    Google Scholar 

  • Lindenmayer JP, Kay SR, Friedman C (1986) Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. Compr Psychiatry 27:276–286

    Google Scholar 

  • Meltzer HY, Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin, pp 68–77

    Google Scholar 

  • Möller H-J (1993) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3:1–11

    Google Scholar 

  • Müller-Spahn F, Modell S, Thomma M (1992) Neue Aspekte in der Diagnostik, Pathogenese und Therapie schizophrener Minussymptomatik. Der Nervenarzt 63:383–400

    Google Scholar 

  • National Institute of Mental Health (1976) Clinical global impressions. In: Guy W (ed) ECDEU Assessment manual for psychopharmacology, revised edition. Rockville, Maryland, pp 217–222

    Google Scholar 

  • Overall JE, Gorham DR (1976) Brief Psychiatric Rating Scale. In: Guy W (ed) ECDEU Assessment manual for psychopharmacology, revised edition. Rockville, Maryland, pp 157–169

Appendix: literature reviewed on clinical trials in patients with negative symptoms

  • Albus M, Botschev C, Müller-Spahn F, Naber D, Münch U, Ackenheil M (1986) Clinical and biochemical effects of nicergoline in chronic schizophrenic patients. Pharmacopsychiatry 19:101–105

    Google Scholar 

  • Alphs L, Lafferman J, Ross L, Bland W, Levine J (1989) Fenfluramine treatment of negative symptoms in older schizophrenic inpatients. Psychopharmacol Bull 25:149–153

    Google Scholar 

  • Barnas C, Stuppäck CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1991) Zotepin: Die Behandlung schizophrener Patienten mit vorherrschender Negativsymptomatik. Eine Doppelblindstudie vs. Haloperidol. Fortschr Neurol Psychiatr: 36–40

  • Bersani G, Bressa GM, Meco G, Marini S, Pozzi F (1990) Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum Psychopharmacol 5:225–231

    Google Scholar 

  • Boyer P (1986) Etude de l'efficacité de faibles doses de neuroleptiques atypiques (benzamides) dans les états déficitaires. Ann Med Psychol 144:593–599

    Google Scholar 

  • Brambilla F, Aguglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R, Catalano M, Drago F (1986) Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 15:114–121

    Google Scholar 

  • Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91:104–108

    Google Scholar 

  • Cesarec Z, Nyman A (1985) Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 71:523–538

    Google Scholar 

  • Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidone versus Haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85:295–305

    Google Scholar 

  • Csernansky JG, Lombrozo L, Gulevich GD, Hollister LE (1984) Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study. J Clin Psychopharmacol 4:349–352

    Google Scholar 

  • Csernansky JG, Riney SJ, Lombroso L, Overall JE, Hollister LE (1988) Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 45:655–659

    Google Scholar 

  • Deo R, Soni S, Rastogi SC, Levine S, Plant I, Edwards JG, Mitchell MJ, Chanas A (1990) A double-blind comparative trial of remoxipride and haloperidol in the treatment of schizophrenia. Hum Psychopharmacol 5:133–141

    Google Scholar 

  • Dieterle DM, Ackenheil M, Müller-Spahn F, Kapfhammer HP (1987) Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 20:52–57

    Google Scholar 

  • Eccleston D, Fairbairn AF, Hassanyeh F, McClelland HA, Stephens DA (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147:623–630

    Google Scholar 

  • Feinberg SS, Kay SR, Elijovich LR, Fiszbein A, Opler LA (1988) Pimozide treatment of the negative schizophrenic syndrome: an open trial. J Clin Psychiatry 49:235–238

    Google Scholar 

  • Fleischhacker WW, Stuppäck C, Barnas C, Unterweger B, Hinterhuber H (1987) Low-dose zotepine in the maintenance treatment of schizophrenia. Pharmacopsychiatry 20:61–63

    Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppäck C, Unterweger B, Hinterhuber H (1987) Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 20:58–60

    Google Scholar 

  • Frangos H, Zissis NP, Leontopoulos I, Diamantas N, Tsitouridis S, Gavriil I, Tsolis K (1978) Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand 57:436–446

    Google Scholar 

  • Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23:206–211

    Google Scholar 

  • Gerbaldo H, Demisch L, Lehmann C-O, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms: Results of an open study. Pharmacopsychiatry 21:387–388

    Google Scholar 

  • Gerlach J, Lühdorf K (1975) The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacology 44:105–110

    Google Scholar 

  • Goff D, Brotman A, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147:492–494

    Google Scholar 

  • Haas S, Beckmann H (1982) Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatry 15:70–74

    Google Scholar 

  • Herrera JM, Alvarez WA, Freinhar JP, Lawson WB, Sramek JJ (1991) Adjunctive clonazepam in the treatment of chronic schizophrenia. Int J Psychosom 38:1–4, 17–20

    Google Scholar 

  • Hommer DW, Pickar D, Roy A, Ninan P, Boronow J, Paul SM (1984) The effects of ceruletide in schizophrenia. Arch Gen Psychiatry 41:617–619

    Google Scholar 

  • Inanaga K, Inoue K, Tachibana H, Oshima M, Kotorii T (1972) Effect of L-dopa in schizophrenia. Folia Psychiatr Neurol Japon 26:145–157

    Google Scholar 

  • Johnstone EC, Frith CD, Crow TJ, Carney MWP (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet April 22:848–851

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozpaine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Kay SR, Opler LA (1985–86) L-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int J Psychiatr Med 15:293–298

    Google Scholar 

  • Kolivakis T, Azim H, Kingstone E (1974) A double-blind comparison of pimozide and chlopromazine in the maintenance care of chronic schizophrenic outpatients. Curr Ther Res 16:998–1004

    Google Scholar 

  • Lapierre YD (1978) A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry 135:956–959

    Google Scholar 

  • Lapierre YD, Lavallee J (1975) Pimozide and the social behavior of schizophrenics. Curr Ther Res 18:181–188

    Google Scholar 

  • Meco G, Bedini L, Bonifati V, Sonsini U (1989) Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 46:876–883

    Google Scholar 

  • Meltzer HY, Bastani B, Young Kwon K, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 99:68–72

    Google Scholar 

  • Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M (1990) Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol 5:83–95

    Google Scholar 

  • Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21:389–390

    Google Scholar 

  • Petit M, Zann M, Lesieur P, Colonna L (1987) The effect of sulpiride on negative symptoms of schizophrenia. Br J Psychiatry 150:270–271

    Google Scholar 

  • Peuskens J (1989) Risperidone: a new approach in the treatment of schizophrenia. Proceeding of a symposium: treatment of negative symptoms in schizophrenia. 8th World Congress of Psychiatry, Athens

  • Serban G, Siegel S, Gaffney M (1992) Response to negative symptoms of schizophrenia to neuroleptic treatment. J Clin Psychiatry 53:229–234

    Google Scholar 

  • Sheppard GP (1979) High-dose propranolol in schizophrenia. Br J Psychiatry 134:470–476

    Google Scholar 

  • Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on, double-blind, placebo-controlled study. Biol Psychiatry 31:698–704

    Google Scholar 

  • Siris S, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988) Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145:1532–1537

    Google Scholar 

  • Siris S, Mason S, Bermanzohn B, Alvir M, McCorry T (1990) Adjunctive imipramine maintenance in postpsychotic depression/negative symptoms. Psychopharmacol Bull 26:91–94

    Google Scholar 

  • Soni SD, Mallik A, Schiff AA (1990) Sulpiride in negative schizophrenia: a placebo-controlled double blind assessment. Hum Psychopharmacol 5:233–238

    Google Scholar 

  • Stahl SM, Uhr SB, Berger PA (1985) Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biol Psychiatry 20:1098–1102

    Google Scholar 

  • Tandon R, Greden J, Silk K (1988) Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 8:212–215

    Google Scholar 

  • Tandon R, Mann N, Eisner W, Coppard N (1990) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 31:235–241

    Google Scholar 

  • Tandon R, Shipley J, Greden J, Mann N, Eisner W, Goodson J (1991) Muscarinic cholinergic hyperactivity in schizophrenia. Schizophr Res 4:23–30

    Google Scholar 

  • Uhr SB, Jackson K, Bergen PA, Csernansky JG (1988) Effects of verapamil administration on negative symptoms of chronic schizophrenia. Psychiatr Res 23:351–352

    Google Scholar 

  • Van Kammen D, Boronow JJ (1988) Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 3:111–121

    Google Scholar 

  • Van Kammen DP, Hommer DW, Malas KL (1987) Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? Neuropsychobiology 18:112–117

    Google Scholar 

  • Wiesel F, Alfredsson G, Bjerkenstedt L, Härnryd C, Oxenstierna G, Sedvall G (1985) Le dogmatil dans le traitement des symptômes négatifs chez des patients schizophrènes. Semin Hôpital Paris 61:1317–1321

    Google Scholar 

  • Wilson L, Roberts R, Gerber C (1982) Pimozide vs chlorpromazine in chronic schizophrenia: a 52-week double-blind study of maintenance therapy. J Clin Psychiatry 43:62–65

    Google Scholar 

  • Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM (1986) Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 143:85–87

    Google Scholar 

  • Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D (1988) Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Arch Gen Psychiatry 45:664–671

    Google Scholar 

  • Yamagami S, Soejima K (1989) Effect of maprotiline combined with conventional neuroleptics against negative symptoms chronic schizophrenia. Drugs Exp Clin Res 15:171–176

    Google Scholar 

  • Yamagami S, Kiriike K, Kawaguchi K (1988) A single-blind study of clocapramine and sulpiride in hospitalised chronic schizophrenic patients. Drugs Exp Clin Res 14:707–713

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Nervenklinik, D-53127, Bonn, Germany

    H. -J. Möller

  2. Academic Psychiatric Centre, NL-6202 AZ, Maastricht, The Netherlands

    H. M. van Praag

  3. Schering AG, D-13353, Berlin, Germany

    B. Aufdembrinke

  4. Charing Cross and Westminster Medical School, London, United Kingdom

    T. R. E. Barnes

  5. Synthélabo Recherche, D-81925, München, Germany

    J. Beck & F. X. Eich

  6. Gaustad Hospital, N-0320, Oslo, Norway

    H. Bentsen

  7. Zeneca Pharmceuticals, Maccelsfield, Cheshire, United Kingdom

    L. Farrow & J. Ryan

  8. Universitätsklinik, A-6020, Innsbruck, Austria

    W. W. Fleischhacker

  9. St. Hans Hospital, DK-4000, Roskilde, Denmark

    J. Gerlach

  10. Astra Arcus AB, S-15185, Södertälje, Sweden

    K. Grafford

  11. Hoechst AG, D-65929, Frankfurt am Main, Germany

    B. Hentschel

  12. Janssen Research Foundation, B-2340, Beerse, Belgium

    S. Heylen

  13. U 302, Hôpital La Salpêtrière, F-75651, Paris Cedex 13, France

    Y. Lecrubier

  14. Fulbourn Hospital, CB1 5EF, Cambridge, United Kingdom

    P. McKenna

  15. Psychiatrische Universitätsklinik, D-55131, Mainz, Germany

    W. Maier

  16. H. Lundbeck AS, DK-2500, Copenhagen Valby, Denmark

    V. Pedersen

  17. Janssen GmbH, D-41470, Neuss, Germany

    A. Rappard

  18. Synthélabo Paris, F-92225, Bagneux Cedex, France

    W. Rein

  19. Novo Nordisk A/S, DK-2760, Maløv, Denmark

    M. Sloth Nielsen

  20. Psychiatrische Universitätsklinik, D-79104, Freiburg, Germany

    R. -D. Stieglitz

  21. E. Merck, D-64293, Darmstadt, Germany

    G. Wegener

  22. Glaxo Group Research Ltd., Greenford, Middlesex, United Kingdom

    J. Wilson

  23. Boehringer Ingelheim Deutschland GmbH, Klinische Forschung Ingelheim, Binger Straße 173, D-55216, Ingelheim am Rhein, Germany

    P. Bailey, A. Hertkorn & J. P. Leonard

Authors
  1. H. -J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. van Praag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Aufdembrinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. R. E. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Bentsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. X. Eich
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Farrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K. Grafford
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. B. Hentschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Hertkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S. Heylen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Y. Lecrubier
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. J. P. Leonard
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. P. McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. W. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. V. Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. A. Rappard
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. W. Rein
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. J. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. M. Sloth Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. R. -D. Stieglitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. G. Wegener
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. J. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möller, H.J., van Praag, H.M., Aufdembrinke, B. et al. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 115, 221–228 (1994). https://doi.org/10.1007/BF02244775

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02244775

Key words

Search

Navigation